Empowering Personalized Melanoma Care with the Merlin™ Test
Crucial tumor insight for personalized melanoma care
Co-developed by SkylineDx and the Mayo Clinic, the Merlin Test is the only non-invasive genomic test for primary cutaneous melanomas that combines clinicopathologic variables (CP) and gene expression profiling (GEP) into a single algorithm (CP-GEP).
The Merlin™ Test Provides:
• An actionable binary result: Low Risk or High Risk
• Patient’s risk of nodal metastasis
• 5-10 year survival outcome
Integrate your medical expertise with the Merlin Test.
Collaborating with leading melanoma experts worldwide, at SkylineDx we are committed to addressing the complex challenges of challenges associated with all stages of cutaneous melanomas.
Genomic testing plays an important role in the decision-making process, offering unique insights into the biology of an individual’s tumor and supporting more personalized treatment strategies.
The Merlin Test provides timely results that guide cutaneous melanoma management including surgical interventions and treatment.
The Merlin Test is covered by Medicare and we have financial support programs in place to assist patients with out-of-pocket expenses.
